Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Liqiang Li, Xinfeng Lin, Lin Wang, Xiaopan Ma, Ziqing Zeng, Futao Liu, Bing Jia, Hua Zhu, Aiwen Wu, Zhi Yang
PURPOSE: An accurate diagnosis of colorectal carcinoma (CRC) can assist physicians in developing reasonable therapeutic regimens, thereby significantly improving the patient's prognosis. Carcinoembryonic antigen (CEA)-targeted PET imaging shows great potential for this purpose. Despite showing remarkable abilities to detect primary and metastatic CRC, previously reported CEA-specific antibody radiotracers or pretargeted imaging are not suitable for clinical use due to poor pharmacokinetics and complicated imaging procedures...
October 2023: European Journal of Nuclear Medicine and Molecular Imaging
#22
JOURNAL ARTICLE
Gitanjali Sharma, Marta C Braga, Chiara Da Pieve, Wojciech Szopa, Tatjana Starzetz, Karl H Plate, Wojciech Kaspera, Gabriela Kramer-Marek
There is no established method to assess the PD-L1 expression in brain tumours. Therefore, we investigated the suitability of affibody molecule (ZPD-L1 ) radiolabelled with F-18 (Al18 F) and Ga-68 to measure the expression of PD-L1 in xenograft mouse models of GBM. Mice bearing subcutaneous and orthotopic tumours were imaged 1 h post-radioconjugate administration. Ex vivo biodistribution studies and immunohistochemistry (IHC) staining were performed. Tumoural PD-L1 expression and CD4+/CD8+ tumour-infiltrating lymphocytes were evaluated in human GBM specimens...
June 9, 2023: Cancers
#23
JOURNAL ARTICLE
Adriana V F Massicano, Patrick N Song, Ameer Mansur, Sharon L White, Anna G Sorace, Suzanne E Lapi
Triple-negative breast cancers (TNBCs) currently have limited treatment options; however, PD-L1 is an indicator of susceptibility to immunotherapy. Currently, assessment of PD-L1 is limited to biopsy samples. These limitations may be overcome with molecular imaging. In this work, we describe chemistry development and optimization, in vitro, in vivo, and dosimetry of [89 Zr]-Atezolizumab for PD-L1 imaging. Atezolizumab was conjugated to DFO and radiolabeled with 89 Zr. Tumor uptake and heterogeneity in TNBC xenograft and patient-derived xenograft (PDX) mouse models were quantified following [89 Zr]-Atezolizumab-PET imaging...
May 11, 2023: Cancers
#24
JOURNAL ARTICLE
Christian W Wichmann, Stan Poniger, Nancy Guo, Peter Roselt, Stacey E Rudd, Paul S Donnelly, Benjamin Blyth, Jessica Van Zuylekom, Angela Rigopoulos, Ingrid J G Burvenich, Laurence Morandeau, Shifaza Mohamed, Anna Nowak, Fiona Hegi-Johnson, Michael MacManus, Andrew M Scott
OBJECTIVES: 89 Zr-labelled proteins are gaining importance in clinical research in a variety of diseases. To date, no clinical study has been reported that utilizes an automated approach for radiosynthesis of 89 Zr-labelled radiopharmaceuticals. We aim to develop an automated method for the clinical production of 89 Zr-labelled proteins and apply this method to Durvalumab, a monoclonal antibody targeting PD-L1 immune-checkpoint protein. PD-L1 expression is poorly understood and can be up-regulated over the course of chemo- and radiotherapy treatment...
May 16, 2023: Nuclear Medicine and Biology
#25
JOURNAL ARTICLE
Bhasker Radaram, Sarah E Glazer, Ping Yang, Chia-Wei Li, Mien-Chie Hung, Seth T Gammon, Mian Alauddin, David Piwnica-Worms
Programmed death ligand 1 (PD-L1) is a type 1 transmembrane immunosuppressive protein that is expressed on a wide range of cell types, including cancer cells. Anti-PD-L1 antibodies have revolutionized cancer therapy and have led to improved outcomes for subsets of cancer patients, including triple-negative breast cancer (TNBC) patients. As a result, PET imaging of PD-L1 protein expression in cancer patients has been explored for noninvasive detection of PD-L1 expressing tumors as well as monitoring response to anti-PD-L1 immune checkpoint therapy...
May 16, 2023: ACS Omega
#26
JOURNAL ARTICLE
Qian Guo, Chuanke Zhao, Xiangyu Gao, Lixin Ding, Pei Wang, Ya'nan Ren, Xingguo Hou, Yuan Yao, Cheng Zhang, Xianteng Yang, Zhi Yang, Hua Zhu
Real-time monitoring of the biological behavior of extracellular vesicles (EVs) in vivo is limited, which hinders its application in biomedicine and clinical translation. A noninvasive imaging strategy could provide us with useful information on EVs' distribution, accumulation and homing in vivo, and pharmacokinetics. In this study, the long half-life radionuclide iodine-124 (124 I) was used to directly label umbilical cord mesenchymal stem cell-derived EVs. The resulting probe, namely, 124 I-MSC-EVs, was manufactured and ready to use within 1 min...
May 22, 2023: Molecular Pharmaceutics
#27
JOURNAL ARTICLE
Yan Chen, Xingguo Hou, Dapeng Li, Jin Ding, Jiayue Liu, Zilei Wang, Fei Teng, Hongjun Li, Fan Zhang, Yi Gu, Steven Yu, Xueming Qian, Zhi Yang, Hua Zhu
Claudin18.2 (CLDN18.2) is a tight junction protein that is overexpressed in a variety of solid tumors such as gastrointestinal cancer and oesophageal cancer. It has been identified as a promising target and a potential biomarker to diagnose tumor, evaluate efficacy, and determine patient prognosis. TST001 is a recombinant humanized CLDN18.2 antibody that selectively binds to the extracellular loop of human Claudin18.2. In this study, we constructed a solid target radionuclide zirconium-89 (89 Zr) labled-TST001 to detect the expression of in the human stomach cancer BGC823CLDN18...
April 2023: Journal of Pharmaceutical Analysis
#28
REVIEW
Sofia C Vaz, Stephanie L Graff, Arlindo R Ferreira, Márcio Debiasi, Lioe-Fee de Geus-Oei
Significant advances in breast cancer (BC) treatment have been made in the last decade, including the use of immunotherapy and, in particular, immune checkpoint inhibitors that have been shown to improve the survival of patients with triple negative BC. This narrative review summarizes the studies supporting the use of immunotherapy in BC. Furthermore, the usefulness of 2-deoxy-2-[18 F]fluoro-D-glucose (2-[18 F]FDG) positron emission/computerized tomography (PET/CT) to image the tumor heterogeneity and to assess treatment response is explored, including the different criteria to interpret 2-[18 F]FDG PET/CT imaging...
May 5, 2023: Cancers
#29
JOURNAL ARTICLE
Kevin P Labadie, Adrienne L Lehnert, Aimee L Kenoyer, Donald K Hamlin, Andrew D Ludwig, Alan F Utria, Sara K Daniel, Tara N Mihailovic, Alexander Prossnitz, Johnnie J Orozco, Yawen Li, D Scott Wilbur, Robert S Miyaoka, James O Park
BACKGROUND: Early intrahepatic recurrence is common after surgical resection of hepatocellular carcinoma (HCC) and leads to increased morbidity and mortality. Insensitive and nonspecific diagnostic imaging contributes to EIR and results in missed treatment opportunities. In addition, novel modalities are needed to identify targets amenable for targeted molecular therapy. In this study, we evaluated a zirconium-89 radiolabeled glypican-3 (GPC3) targeting antibody conjugate (89 Zr-αGPC3) for use in positron emission tomography (PET) for detection of small, GPC3+ HCC in an orthotopic murine model...
April 27, 2023: EJNMMI Research
#30
JOURNAL ARTICLE
Noor Jailkhani, Karl R Clauser, Howard H Mak, Steffen Rickelt, Chenxi Tian, Charles A Whittaker, Kenneth K Tanabe, Stephen R Purdy, Steven A Carr, Richard O Hynes
Metastases are hard to detect and treat, and they cause most cancer-related deaths. The relative lack of therapies targeting metastases represents a major unmet clinical need. The extracellular matrix (ECM) forms a major component of the tumor microenvironment in both primary and metastatic tumors, and certain ECM proteins can be selectively and abundantly expressed in tumors. Nanobodies against ECM proteins that show selective abundance in metastases have the potential to be used as vehicles for delivery of imaging and therapeutic cargoes...
April 26, 2023: Cancer Research
#31
REVIEW
Janke Kleynhans, Mike Machaba Sathekge, Thomas Ebenhan
It is important to constantly monitor developments in the preclinical imaging arena of infection. Firstly, novel radiopharmaceuticals with the correct characteristics must be identified to funnel into the clinic. Secondly, it must be evaluated if enough innovative research is being done and adequate resources are geared towards the development of radiopharmaceuticals that could feed into the Nuclear Medicine Clinic in the near future. It is proposed that the ideal infection imaging agent will involve PET combined with CT but more ideally MRI...
April 1, 2023: Seminars in Nuclear Medicine
#32
JOURNAL ARTICLE
Stanley Fayn, A Paden King, Nicholas T Gutsche, Zhijian Duan, Jesse Buffington, Colleen P Olkowski, Ying Fu, Jessica Hong, Deepak Sail, Kwamena E Baidoo, Rolf E Swenson, Ross W Cheloha, Mitchell Ho, Peter Choyke, Freddy Escorcia
Primary liver cancer is the third leading cause of cancer-related deaths, and its incidence and mortality are increasing worldwide. Hepatocellular carcinoma (HCC) accounts for 80% of primary liver cancer cases. Glypican-3 (GPC3) is a heparan sulfate proteoglycan that histopathologically defines HCC and represents an attractive tumor-selective marker for radiopharmaceutical imaging and therapy for this disease. Single-domain antibodies are a promising scaffold for imaging because of their favorable pharmacokinetic properties, good tumor penetration, and renal clearance...
March 30, 2023: Journal of Nuclear Medicine
#33
JOURNAL ARTICLE
Dai Shi, Zhan Xu, Yuan Cheng, Qingyu Lin, Zhan Si, Wenhui Fu, Tingting Yang, Hongcheng Shi, Dengfeng Cheng
Low β-2-[18 F]-fluoro-2-deoxy-d-glucose (18 F-FDG) uptake in gastric mucinous adenocarcinoma may cause false-negative diagnosis and erroneous staging. Thus, there is an urgent need for developing tumor-specific imaging agents in gastric cancer diagnostics. Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane protein expressed on the surface of tumor-associated macrophages (TAMs) and is considerably overexpressed in tumor tissues. This study aimed to develop new human TREM2 (hTREM2)-targeting imaging agents to diagnose and monitor gastric cancer...
March 23, 2023: Molecular Pharmaceutics
#34
JOURNAL ARTICLE
Iris H C Miedema, Marc C Huisman, Gerben J C Zwezerijnen, Rolf Grempler, Alejandro Perez Pitarch, Andrea Thiele, Raphael Hesse, Mabrouk Elgadi, Alexander Peltzer, Danielle J Vugts, Guus A M S van Dongen, Tanja D de Gruijl, C Willemien Menke-van der Houven van Oordt, Idris Bahce
PURPOSE: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [89 Zr]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration. METHODS: Patients with head and neck (N = 2) or lung cancer (N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3)...
March 2, 2023: European Journal of Nuclear Medicine and Molecular Imaging
#35
REVIEW
Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Malik E Juweid, Kamal Al-Rabi, Mohammad Ma'koseh, Hikmat Abdel-Razeq, Asem Mansour
Cancer immunotherapy has been extensively investigated in lymphoma over the last three decades. This new treatment modality is now established as a way to manage and maintain several stages and subtypes of lymphoma. The establishment of this novel therapy has necessitated the development of new imaging response criteria to evaluate and follow up with cancer patients. Several FDG PET/CT-based response criteria have emerged to address and encompass the various most commonly observed response patterns. Many of the proposed response criteria are currently being used to evaluate and predict responses...
February 7, 2023: Cancers
#36
JOURNAL ARTICLE
H Adams, E M W van de Garde, D J Vugts, J C Grutters, Wim J G Oyen, R G Keijsers
INTRODUCTION: Immune-mediated interstitial pneumonitis may be treated with anti-CD20 therapy after failure of conventional therapies. However, clinical response is variable. It was hypothesized that autoreactive CD20-positive cells may play an important role in this variability. This prospective study aims to elucidate if imaging of CD20-positive cells in the lungs allows prediction of the response to anti-CD20 treatment. METHODS: Twenty-one patients with immune-mediated interstitial lung disease (ILD) with deteriorated pulmonary function received a dose of 1000 mg rituximab on day 1 and day 14 spiked with a tracer dose of radiolabeled [89Zr]-rituximab...
February 24, 2023: European Journal of Nuclear Medicine and Molecular Imaging
#37
JOURNAL ARTICLE
Jessica E Wijngaarden, Marc C Huisman, Yvonne W S Jauw, Guus A M S van Dongen, Henri N J M Greuter, Robert C Schuit, Matthew Cleveland, Elske C Gootjes, Daniëlle J Vugts, C Willemien Menke-van der Houven van Oordt, Ronald Boellaard
PURPOSE: Positron emission tomography imaging of zirconium-89-labelled monoclonal antibodies (89 Zr-Immuno-PET) allows for visualisation and quantification of antibody uptake in tumours in vivo. Patlak linearization provides distribution volume (VT ) and nett influx rate (Ki ) values, representing reversible and irreversible uptake, respectively. Standardised uptake value (SUV) and tumour-to-plasma/tumour-to-blood ratio (TPR/TBR) are often used, but their validity depends on the comparability of plasma kinetics and clearances...
February 23, 2023: European Journal of Nuclear Medicine and Molecular Imaging
#38
JOURNAL ARTICLE
Laura Evangelista, Andrea Bianchi, Alessio Annovazzi, Rosa Sciuto, Silvia Di Traglia, Matteo Bauckneht, Francesco Lanfranchi, Silvia Morbelli, Anna Giulia Nappi, Cristina Ferrari, Giuseppe Rubini, Stefano Panareo, Luca Urso, Mirco Bartolomei, Davide D'Arienzo, Tullio Valente, Virginia Rossetti, Paola Caroli, Federica Matteucci, Demetrio Aricò, Michelangelo Bombaci, Domenica Caponnetto, Francesco Bertagna, Domenico Albano, Francesco Dondi, Sara Gusella, Alessandro Spimpolo, Cinzia Carriere, Michele Balma, Ambra Buschiazzo, Rosj Gallicchio, Giovanni Storto, Livia Ruffini, Veronica Cervati, Roberta Eufrasia Ledda, Anna Rita Cervino, Lea Cuppari, Marta Burei, Giuseppe Trifirò, Elisabetta Brugola, Carolina Arianna Zanini, Alessandra Alessi, Valentina Fuoco, Ettore Seregni, Désirée Deandreis, Virginia Liberini, Antonino Maria Moreci, Salvatore Ialuna, Sabina Pulizzi, Maria Luisa De Rimini
AIM: To examine the role of [18F]FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors. METHODS: Data recorded in a multicenter ( n = 17), retrospective database between March and November 2021 were analyzed. The sample included patients with a confirmed diagnosis of a solid tumor who underwent serial [18F]FDG PET/CT (before and after one or more cycles of immunotherapy), who were >18 years of age, and had a follow-up of at least 12 months after their first PET/CT scan...
January 31, 2023: Cancers
#39
REVIEW
Edel Noriega-Álvarez, José Martín-Comín
Inflammatory bowel diseases (IBD) are chronic immune-mediated inflammatory diseases affecting the gastrointestinal tract. Classically, two subtypes of IBD are recognized: Ulcerative colitis and Crohn's disease. There is not a single and reliable test for IBD diagnosis but the nuclear medicine techniques like 99m Tc-HMPAO autologous labelled leukocytes scintigraphy (WBCS) and PET/CT plays a role in the management of IBD. Leukocytes can be labelled "in vitro" (using 99m Tc-HMPAO in Europe or 111 In-oxine in America) or "in vivo" using antigranulocyte monoclonal antibodies...
March 2023: Seminars in Nuclear Medicine
#40
JOURNAL ARTICLE
Csaba Csikos, Adrienn Vágner, Gábor Nagy, Ibolya Kálmán-Szabó, Judit P Szabó, Minh Toan Ngo, Zoltán Szoboszlai, Dezső Szikra, Zoárd Tibor Krasznai, György Trencsényi, Ildikó Garai
Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission tomography using radiolabeled target-specific antibodies (immuno-PET) provides the longitudinal and quantitative assessment of tumor target expression. Due to antibodies having a long-circulating time, radioactive metal ions (e...
January 8, 2023: Diagnostics
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
